Reviewed,
UniProtKB/Swiss-Prot P07949 (RET_HUMAN)
Last modified
November 25, 2008.
Version 131.
History...
Clusters with 100%,
90%,
50% identity |
Documents (7) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Proto-oncogene tyrosine-protein kinase receptor ret Short name=C-ret EC=2.7.10.1 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 1114 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is further processed into a mature form. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Probable receptor with tyrosine-protein kinase activity; important for development. |
| Catalytic activity | ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. |
| Subunit structure | Phosphorylated form interacts with the PBT domain of DOK2, DOK4 and DOK5 By similarity. |
| Subcellular location | |
| Post-translational modification | Phosphorylated. Autophosphorylated on C-terminal tyrosine residues upon ligand stimulation. |
| Polymorphism | The Cys-982 polymorphism may be associated with an increased risk for developing Hirschsprung disease. |
| Involvement in disease | Defects in RET may be a cause of colorectal cancer (CRC) [MIM:114500]. Defects in RET are a cause of Hirschsprung disease (HSCR) [MIM:142623]. HSCR is a genetic disorder of neural crest development characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction. Occasionally, MEN2A or FMTC occur in association with HSCR. Defects in RET are the cause of medullary thyroid carcinoma (MTC) [MIM:155240]. MTC is a rare tumor derived from the C cells of the thyroid. Three hereditary forms are known, that are transmitted in an autosomal dominant fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases and where MTC is the only clinical manifestation. Defects in RET are the cause of multiple neoplasia type 2B (MEN2B) [MIM:162300]. MEN2B is an uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophtalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases. Defects in RET are a cause of pheochromocytoma [MIM:171300]. The pheochromocytomas are catecholamine-producing, chromaffin tumors that arise in the adrenal medulla in 90% of cases. In the remaining 10% of cases, they develop in extra-adrenal sympathetic ganglia and may be referred to as "paraganglioma." Pheochromocytoma usually presents with hypertension. Approximately 10% of pheochromocytoma is hereditary. The genetic basis for most cases of non-syndromic familial pheochromocytoma is unknown. Defects in RET are the cause of multiple neoplasia type 2A (MEN2A) [MIM:171400]; also called multiple neoplasia type 2 (MEN2). MEN2A, the most frequent form of MTC, is an inherited cancer syndrome characterized by MTC, phaeochromocytoma and/or hyperparathyroidism. Chromosomal aberrations involving RET are a cause of thyroid papillary carcinoma (PACT) [MIM:188550]. Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene; inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene; translocation t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5) oncogene; translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion; translocation t(6;10)(p21.3;q11.2) with RFP generates the Delta RFP/RET oncogene; translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7) oncogene; translocation t(7;10)(q32;q11) with TIF1 generates the TIF1/RET (PTC6) oncogene. The PTC5 oncogene has been found in 2 cases of PACT in children exposed to radioactive fallout after Chernobyl. Defects in RET are a cause of renal adysplasia [MIM:191830]; also known as renal agenesis or renal aplasia. Renal agenesis refers to the absence of one (unilateral) or both (bilateral) kidneys at birth. Bilateral renal agenesis belongs to a group of perinatally lethal renal diseases, including severe bilateral renal dysplasia, unilateral renal agenesis with contralateral dysplasia and severe obstructive uropathy. Defects in RET are a cause of congenital central hypoventilation syndrome (CCHS) [MIM:209880]; also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. |
| Sequence similarities | Belongs to the protein kinase superfamily. Tyr protein kinase family. Contains 1 cadherin domain. Contains 1 protein kinase domain. |
Ontologies
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||
Molecule processing | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Signal peptide | 1 – 28 | 28 | Potential | ||||||
| Chain | 29 – 1114 | 1086 | Proto-oncogene tyrosine-protein kinase receptor ret | PRO_0000024450 | |||||
Regions | |||||||||
| Topological domain | 29 – 635 | 607 | Extracellular Potential | ||||||
| Transmembrane | 636 – 657 | 22 | Potential | ||||||
| Topological domain | 658 – 1114 | 457 | Cytoplasmic Potential | ||||||
| Domain | 168 – 272 | 105 | Cadherin | ||||||
| Domain | 724 – 1016 | 293 | Protein kinase | ||||||
| Nucleotide binding | 730 – 738 | 9 | ATP By similarity | ||||||
Sites | |||||||||
| Active site | 874 | 1 | Proton acceptor By similarity | ||||||
| Binding site | 758 | 1 | ATP By similarity | ||||||
| Site | 712 – 713 | 2 | Breakpoint for translocation to form PCM1-RET; RET-CCDC6; RET-GOLGA5; RET-TIF1 and RET-TRIM33 oncogenes | ||||||
Amino acid modifications | |||||||||
| Modified residue | 806 | 1 | Phosphotyrosine; by autocatalysis | ||||||
| Modified residue | 809 | 1 | Phosphotyrosine; by autocatalysis | ||||||
| Modified residue | 900 | 1 | Phosphotyrosine; by autocatalysis | ||||||
| Modified residue | 905 | 1 | Phosphotyrosine; by autocatalysis | ||||||
| Modified residue | 981 | 1 | Phosphotyrosine; by autocatalysis | ||||||
| Modified residue | 1015 | 1 | Phosphotyrosine; by autocatalysis | ||||||
| Modified residue | 1062 | 1 | Phosphotyrosine; by autocatalysis | ||||||
| Modified residue | 1090 | 1 | Phosphotyrosine; by autocatalysis | ||||||
| Modified residue | 1096 | 1 | Phosphotyrosine; by autocatalysis | ||||||
| Glycosylation | 98 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 151 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 199 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 336 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 343 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 361 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 367 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 377 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 394 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 448 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 468 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 554 | 1 | N-linked (GlcNAc...) Potential | ||||||
Natural variations | |||||||||
| Natural variant | 20 | 1 | P → L in HSCR; sporadic form. | VAR_009459 | |||||
| Natural variant | 32 | 1 | S → L in HSCR; familial form. | VAR_006295 | |||||
| Natural variant | 40 | 1 | L → P in HSCR. | VAR_009492 | |||||
| Natural variant | 64 | 1 | P → L in HSCR; familial form. | VAR_006296 | |||||
| Natural variant | 67 | 1 | R → H in CCHS. | VAR_018153 | |||||
| Natural variant | 77 | 1 | R → C in HSCR. | VAR_009460 | |||||
| Natural variant | 93 | 1 | G → S in HSCR; could be a rare polymorphism. | VAR_006297 | |||||
| Natural variant | 114 | 1 | R → H in CCHS. | VAR_018154 | |||||
| Natural variant | 142 | 1 | C → S in HSCR; sporadic form. | VAR_006298 | |||||
| Natural variant | 145 | 1 | V → G in a colorectal cancer sample; somatic mutation. | VAR_035711 | |||||
| Natural variant | 157 | 1 | C → Y in HSCR; could be a polymorphism. | VAR_009461 | |||||
| Natural variant | 163 | 1 | R → Q in a colorectal adenocarcinoma sample; somatic mutation. | VAR_041762 | |||||
| Natural variant | 174 | 1 | F → S in HSCR; sporadic form. | VAR_009462 | |||||
| Natural variant | 180 | 1 | R → P in HSCR; sporadic form. | VAR_009463 | |||||
| Natural variant | 197 | 1 | C → Y in HSCR; sporadic form. | VAR_009464 | |||||
| Natural variant | 198 | 1 | P → T in renal adysplasia; prevents phosphorylation in response to GDNF. | VAR_044392 | |||||
| Natural variant | 231 | 1 | R → H in HSCR; familial form. | VAR_006299 | |||||
| Natural variant | 251 | 1 | E → K in HSCR; familial form. | VAR_006300 | |||||
| Natural variant | 278 | 1 | T → N: dbSNP rs35118262. | VAR_041763 | |||||
| Natural variant | 287 | 1 | R → Q in HSCR; sporadic form. | VAR_006301 | |||||
| Natural variant | 292 | 1 | V → M: dbSNP rs34682185. | VAR_041764 | |||||
| Natural variant | 313 | 1 | R → Q in HSCR; sporadic form. | VAR_009465 | |||||
| Natural variant | 330 | 1 | R → Q in HSCR. | VAR_006302 | |||||
| Natural variant | 359 | 1 | N → K in HSCR; could be a polymorphism. | VAR_009466 | |||||
| Natural variant | 360 | 1 | R → W in HSCR. | VAR_009467 | |||||
| Natural variant | 376 | 1 | V → A in renal adysplasia; constitutively phosphorylated; expressed only the immature intracellular form. | VAR_044393 | |||||
| Natural variant | 393 | 1 | F → L in HSCR; familial form. | VAR_006303 | |||||
| Natural variant | 394 | 1 | N → H in renal adysplasia; prevents phosphorylation in response to GDNF. | VAR_044394 | |||||
| Natural variant | 394 | 1 | N → K in HSCR. | VAR_009468 | |||||
| Natural variant | 399 | 1 | P → L in HSCR; sporadic form. | VAR_006304 | |||||
| Natural variant | 432 | 1 | A → E in CCHS. | VAR_018155 | |||||
| Natural variant | 475 | 1 | R → Q in HSCR; sporadic form. | VAR_006305 | |||||
| Natural variant | 489 | 1 | D → N: dbSNP rs9282834. | VAR_018156 | |||||
| Natural variant | 531 | 1 | C → CEEC in MTC; familial form. | VAR_009469 | |||||
| Natural variant | 593 | 1 | G → E in a colorectal cancer sample; somatic mutation. | VAR_035712 | |||||
| Natural variant | 600 | 1 | R → Q Probably a rare polymorphism. | VAR_008966 | |||||
| Natural variant | 609 | 1 | C → G in MEN2A. | VAR_009470 | |||||
| Natural variant | 609 | 1 | C → R in MEN2A. | VAR_009471 | |||||
| Natural variant | 609 | 1 | C → W in HSCR; familial form. | VAR_006307 | |||||
| Natural variant | 609 | 1 | C → Y in MTC, MEN2A and HSCR; familial and sporadic forms. | VAR_006306 | |||||
| Natural variant | 611 | 1 | C → G in MTC; familial form. | VAR_009472 | |||||
| Natural variant | 611 | 1 | C → R in MEN2A. | VAR_009473 | |||||
| Natural variant | 611 | 1 | C → S in MEN2A. | VAR_009474 | |||||
| Natural variant | 611 | 1 | C → W in MEN2A and MTC; familial form. | VAR_006308 | |||||
| Natural variant | 611 | 1 | C → Y in MEN2A. | VAR_006309 | |||||
| Natural variant | 618 | 1 | C → F in MEN2A and MTC; familial form. | VAR_006312 | |||||
| Natural variant | 618 | 1 | C → G in MEN2A. | VAR_006310 | |||||
| Natural variant | 618 | 1 | C → R in MEN2A, MTC and HSCR. | VAR_006311 | |||||
| Natural variant | 618 | 1 | C → S in MEN2A, HSCR and MTC; familial and sporadic forms. | VAR_006313 | |||||
| Natural variant | 618 | 1 | C → Y in MEN2A and MTC; familial form. | VAR_006314 | |||||
| Natural variant | 620 | 1 | C → F in MEN2A and MTC; familial form. | VAR_006318 | |||||
| Natural variant | 620 | 1 | C → G in MEN2A and MTC; familial and sporadic forms. | VAR_006315 | |||||
| Natural variant | 620 | 1 | C → R in MEN2A, MTC and HSCR; familial and sporadic forms. | VAR_006316 | |||||
| Natural variant | 620 | 1 | C → S in MEN2A and MTC; familial form. | VAR_006317 | |||||
| Natural variant | 620 | 1 | C → W in MEN2A and HSCR. | VAR_009475 | |||||

Clusters with